Pharmaxis Ltd (PXS) expects to be in a position to make an announcement concerning its European marketing application for Bronchitol® for the treatment of cystic fibrosis by approximately 8.30am Wednesday 25 May 2011.The announcement will have the effect of lifting the current trading halt over the company's shares.

The company will hold an investor teleconference at 9.30am Wednesday 25 May to discuss the results.

Online access: https://services.choruscall.com/links/pharmaxis110525.html

Dial-in numbers for participants are as follows:

• Australia: 1800 838 758
• USA/Canada: 1877 642 9125
• UK: 0800 635 0664
• NZ: 0800 446 958
• Switzerland: 0800 001 230
• Singapore: 800 120 4406
• Hong Kong: 800 962 283
• Other International Metered: +61 7 3107 0210